BioSpace News Archive

XVIVO Perfusion AB Invitation to attend XVIVO’s conference call regarding the presentation of the Report on Operations 2023.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.

Arena BioWorks announced today its launch as a biomedical research institute with a mission to uncover mechanisms of disease by engaging in basic biological research that will be translated into lifesaving biotech therapeutics.

IDEXX Laboratories, Inc. announces the launch of the IDEXX inVue Dx™ Cellular Analyzer, a first-of-its-kind slide-free cellular analyzer to detect the most common cytologic changes found in ear and blood samples.

IDEXX Laboratories, Inc. announced the expansion of its Fecal Dx ® antigen testing platform with the addition of Cystoisospora.

Qilian International Holding Group Limited today announced that on January 10, 2024, the Company received a written notification from the Nasdaq’s Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq’s minimum bid price requirement.

RemeGen Co. Ltd. announced recently that its independently developed mesothelin -targeting antibody-drug conjugate, RC88, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.

SimBioSys is pleased to announce the strategic appointment of Dr. Barry Rosen as its Chief Medical Officer.

BioInvent International AB announced that its early discovery partner Exelixis, Inc. has provided a notice of termination for the option and license agreement for novel antibodies for use in immuno-oncology therapeutics.

Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.